A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow)

A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Sodium Hyaluronate to provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow).

开始日期2025-09-01

申办/合作机构

Anika Therapeutics, Inc.

NCT06353893 / Enrolling by invitationN/AIIT

Postoperative MRI Evaluation of the Integrity Bio-inductive Implant Augmentation of Rotator Cuff Tears of the Shoulder

The goal of this observational study is to evaluate the effectiveness and safety of the Integrity bio-inductive implant in treating partial and full thickness rotator cuff tears. The main questions it aims to answer are:
How does the application of the Integrity implant affect patient-reported outcome measures (PROMs) such as ASES, SANE, and PROMIS?
What are the imaging characteristics of the rotator cuff tears at 3 and 6 months postoperatively when using the Integrity implant?
Postoperative MRIs will be obtained from 10 consecutive patients who have undergone rotator cuff repair using the Integrity implant at 3 and 6 months after surgery. Participants include those with partial and full thickness tears treated with different surgical techniques involving the implant. They may receive either isolated onlay use of the graft for partial tears or augmentation of a standard single or double row repair with the graft applied to the superior surface of the repair.

开始日期2024-04-01

申办/合作机构

Anika Therapeutics, Inc.

NCT04640961 / CompletedN/A

A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (CINGAL®) to Provide Symptomatic Relief of Osteoarthritis of Shoulder Joint

This Trial will obtain clinical data to support an expanded indication for a single injection of Cingal used for the symptomatic relief of osteoarthritis in the shoulder joint.

开始日期2021-01-16

申办/合作机构

Anika Therapeutics, Inc.

100 项与 Anika Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Anika Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Anika Therapeutics, Inc. 相关的文献（医药）

2011-02-01·Journal of materials science. Materials in medicine3区 · 工程技术

Preparation and characterization of a new gellan gum and sulphated hyaluronic acid hydrogel designed for epidural scar prevention

3区 · 工程技术

Article

作者: Davide Bellini ; Claudia Cencetti ; Cristina Longinotti ; Andrea Martinelli ; Pietro Matricardi

Postsurgical adhesions are a common problem in clinical practice, causing nerve compression, pain and discomfort. A new hydrogel based on gellan gum and sulphated hyaluronic acid was synthesized, with the aim to create an effective barrier for epidural scar formation. Physico-chemical properties of the gel were analyzed, and preliminary biocompatibility data (i.e. cytotoxicity) have been collected in view of its potential clinical use. The characterization of the new material demonstrated that the hydrogel, due to its high-viscosity, could effectively act as a barrier with a long in situ residence time. In addition, the hydrogel can be easily extruded from a syringe and its structure exhibits excellent stabilizing properties. Furthermore, biological assays showed that this gel is suitable for further preclinical development.

2006-07-01·Tissue engineering

Maturation of Tissue Engineered Cartilage Implanted in Injured and Osteoarthritic Human Knees

Article

作者: Pavesio, Alessandra ; Zanasi, Stefano ; Soranzo, Carlo ; Sims, Trevor J. ; Luca, Claudio De ; Cortivo, Roberta ; Kon, Elisaveta ; Abatangelo, Giovanni ; Dickinson, Sally C. ; Borrione, Anna ; Brun, Paola ; Marcacci, Maurilio ; Hollander, Anthony P.

The regeneration of damaged organs requires that engineered tissues mature when implanted at sites of injury or disease. We have used new analytic techniques to determine the extent of tissue regeneration after treatment of knee injury patients with a novel cartilage tissue engineering therapy and the effect of pre-existing osteoarthritis on the regeneration process. We treated 23 patients, with a mean age of 35.6 years, presenting with knee articular cartilage defects 1.5 cm2 to 11.25 cm2 (mean, 5.0 cm2) in area. Nine of the patients had X-ray evidence of osteoarthritis. Chondrocytes were isolated from healthy cartilage removed at arthroscopy. The cells were cultured for 14 days, seeded onto esterified hyaluronic acid scaffolds (Hyalograft C), and grown for a further 14 days before implantation. A second-look biopsy was taken from each patient after 6 to 30 months (mean, 16 months). After standard histological analysis, uncut tissue was further analyzed using a newly developed biochemical protocol involving digestion with trypsin and specific, quantitative assays for type II collagen, type I collagen, and proteoglycan, as well as mature and immature collagen crosslinks. Cartilage regeneration was observed as early as 11 months after implantation and in 10 out of 23 patients. Tissue regeneration was found even when implants were placed in joints that had already progressed to osteoarthrosis. Cartilage injuries can be effectively repaired using tissue engineering, and osteoarthritis does not inhibit the regeneration process.

2003-01-01·Novartis Foundation symposium

Hyaluronan-based scaffolds (Hyalograft C) in the treatment of knee cartilage defects: preliminary clinical findings.

Review

作者: Zanasi, Stefano ; Abatangelo, Giovanni ; Marcacci, Maurilio ; Pavesio, Alessandra ; Brocchetta, Domenico ; Borrione, Anna ; Torasso, Francesca ; Hollander, Anthony P ; Kon, Elizaveta

Hyalograft C is an innovative tissue-engineering approach for the treatment of knee cartilage defects involving the implantation of laboratory expanded autologous chondrocytes grown on a three-dimensional hyaluronan-based scaffold. This technique has recently been introduced into clinical practice, with more than 600 patients treated so far. Because no periosteal coverage is required to keep the graft in place, surgical time and morbidity are reduced, and handling of the graft is much simpler than currently available autologous chondrocyte implantation techniques. The safety profile of the treatment appears positive, with a limited number of adverse events reported. Here we discuss the clinical, arthroscopic and histological results from a cohort of 67 patients treated with Hyalograft C (mean follow-up time from implantation of 17.5 months). Results are reported based on four endpoints: patients' subjective evaluation of knee conditions (97% of patients improved) and quality of life (94% improved), surgeons' knee functional test (87% of patients with the best scores), arthroscopic evaluation of cartilage repair (96.7% biologically acceptable) and histological assessment of the grafted site (majority of specimens hyaline-like). The positive clinical results obtained indicate that Hyalograft C may be a viable therapeutic option for the treatment of acute cartilage lesions.

项与 Anika Therapeutics, Inc. 相关的新闻（医药）

2024-10-31

·PRNewswire

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

WEST BRIDGEWATER, Mass., Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that Arthrosurface's position as a leader in orthopedic joint preservation solutions will resume with its portfolio of innovative products and expertise. Continue Reading arthrosurface company logo Arthrosurface: A Pioneer in Joint Restoration and Preservation Shane Shankle, who was appointed Arthrosurface's new President said, "As a leader in joint preservation, I'm excited to drive our company's growth plan by delivering products that help patients maintain an active quality of life." Frank Fedorowicz, Chief Operating and Financial Officer, added, "I'm very happy to be reunited with many of our founding executives to propel Arthrosurface into its next exciting phase." With a commitment to minimally invasive techniques, Arthrosurface products are designed to restore natural joint function while preserving surrounding bone and tissue. Arthrosurface's product portfolio includes more than 150 different surface implant curvatures for the knee, shoulder, wrist and toe that are designed to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. Andrea Patisteas, Senior Executive Vice President emphasized that "With over two decades of clinical experience with our implants, we're thrilled to continue working with physicians and patients to provide them with options for the treatment of orthopedic conditions." Steven Tallarida, President and CEO of Primo Medical Group simply commented "It is great to be back!" Phoenix Brio will be Arthrosurface's parent company, and both will be based in West Bridgewater, Massachusetts. "The acquisition of Arthrosurface aligns with our mission to create and deliver innovative medical solutions that address today's clinical needs. Arthrosurface is a natural fit for us," said Chris LaPlante, CFO at Primo Medical Group. Customers and distributors of Arthrosurface products should not expect to see any change in service or disruption in product access or availability. About Primo Medical Group Primo Medical Group offers the most comprehensive outsourcing solutions for the medical device market, including OEM product distribution services, engineering services, precision component production, finished goods assembly, medical device refurbishment, reusable surgical kit management and complete supply chain management. Established in 1953, Primo Medical Group is a privately held company with five facilities in Massachusetts. Primo Medical Group is an FDA Registered Contract Manufacturer and is compliant with FDA Quality Systems Regulations. Primo Medical Group is also ISO 13485:2016 certified and is a registered manufacturer with the Office of Defense Trade Controls Compliance. Over the past 24 years Primo Medical Group has incubated and co-funded several new technologies including Angiolink Corporation (acquired by Medtronic), Arthrosurface (acquired by Anika Therapeutics), Spirus Medical, Inc. (acquired by Olympus), Saphena Medical Inc. (acquired by a major strategic in 2024), Cardiosolutions, Inc., Trax Surgical, Inc. and Versago Vascular Access. For media inquiries, please contact: Andrea Patisteas 781-828-4400 [email protected] SOURCE Primo Medical Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购

2024-10-17

·BioSpace

Anika Announces Third Quarter 2024 Results Conference Call Date

BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 31842. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika’s website, . The call will be archived and accessible on the same website shortly after its conclusion. About Anika Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit . ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc. For Investor Inquiries: Anika Therapeutics, Inc. Matt Hall, 781-457-9554 Director, Corporate Development and Investor Relations investorrelations@anika.com

财报

2024-07-05

·Pharmaceutical Technology

Pendopharm and Ascendis to distribute hypoparathyroidism treatment

Chronic hypoparathyroidism is a rare endocrine disorder characterised by low or inadequate levels of PTH. Credit: Pixel-Shot / Shutterstock. Pharmascience unit Pendopharm has entered an exclusive distribution agreement with Ascendis Pharma to bring the hypoparathyroidism treatment TransCon PTH (palopegteriparatide) to the Canadian market. Pendopharm will be responsible for securing regulatory approval and overseeing the commercialisation of the product in the country. Neither companies has disclosed the financial terms of the deal. Ascendis Pharma executive vice-president and chief commercial officer Camilla Harder Hartvig stated: “We are delighted to partner with Pendopharm to bring TransCon PTH to Canada, contributing to our shared goal of making a meaningful difference in the lives of patients living with chronic hypoparathyroidism.” A parathyroid hormone (PTH) replacement therapy, TransCon PTH is aimed at treating chronic hypoparathyroidism, a rare endocrine disorder characterised by low or inadequate levels of PTH. See Also: HF-158K1 by HighField Biopharmaceuticals for Bladder Cancer: Likelihood of Approval Innovent sells its share in CAR T-cell therapy to IASO Bio for 18% equity The therapy has already secured approval in the European Union, the European Economic Area and Great Britain under the brand name YORVIPATH, specifically for adult patients. TransCon PTH is undergoing development for the same indication in the US, Japan and other international markets. Pendopharm vice-president and GM Jad Isber stated: “This partnership represents Pendopharm’s commitment to bringing innovative medicines that address unmet medical needs to Canadian patients. “We look forward to working with Canadian endocrinologists to make TransCon PTH available to all patients who may benefit from it.” In May 2024, Pendopharm announced the renewal of a distribution agreement with Anika Therapeutics for Cingal, Monovisc and Orthovisc up to 2030.